文献速递糖尿病

替尔泊肽与基础胰岛素对2型糖尿病不同基线血糖模式患者的疗效:SURPASS-3和SURPASS-4试验的事后分析

Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.
PubMed 文献 · Diabetes Care · 2024-01-01

本事后分析评估替尔泊肽(5、10、15 mg)与德谷胰岛素(SURPASS-3)或甘精胰岛素(SURPASS-4)治疗52周时,根据空腹血清葡萄糖(FSG)和餐后血糖(PPG)中位数划分的不同基线血糖模式亚组的血糖参数变化。结果显示所有替尔泊肽剂量和基础胰岛素均使各亚组HbA1c、FSG和PPG较基线下降(P<0.05),且各亚组内替尔泊肽的HbA1c和PPG降幅大于胰岛素(P<0.05),FSG降幅总体相似,未见FSG/PPG亚组间疗效差异。

要点

  • 各替尔泊肽剂量和基础胰岛素均使所有FSG/PPG亚组的HbA1c、FSG和PPG较基线下降(P<0.05)。
  • 各亚组内替尔泊肽的HbA1c和PPG降幅大于胰岛素(P<0.05),FSG降幅总体相似。
  • 未见FSG/PPG亚组间疗效差异;无论基线血糖模式如何,替尔泊肽的血糖控制均优于胰岛素。

核心结论

  • 在此事后分析中,无论基线血糖模式如何,替尔泊肽的血糖控制均优于胰岛素。

研究设计与样本

  • SURPASS-3和SURPASS-4试验的事后分析,评估替尔泊肽(5、10、15 mg)与德谷胰岛素(SURPASS-3)或甘精胰岛素(SURPASS-4)治疗52周时,根据FSG和PPG中位数划分的四个亚组(低FSG/低PPG、低FSG/高PPG、高FSG/低PPG、高FSG/高PPG)的血糖参数变化。

主要发现

  • 所有替尔泊肽剂量和基础胰岛素均使各亚组HbA1c、FSG和PPG从基线至第52周下降(P<0.05)。
  • 各亚组内,替尔泊肽的HbA1c和PPG降幅大于胰岛素(P<0.05)。
  • 各亚组内,替尔泊肽与胰岛素的FSG降幅总体相似。
  • 未见FSG/PPG亚组间的疗效差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG) and postprandial glucose (PPG) values. RESEARCH DESIGN AND METHODS: Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures. RESULTS: All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.05). Within each subgroup, HbA1c and PPG decreases were greater with tirzepatide than insulin (P < 0.05). FSG decreases were generally similar. There were no differential treatment effects by FSG/PPG subgroup. CONCLUSIONS: In this post hoc analysis, tirzepatide was associated with superior glycemic control compared with insulin, irrespective of baseline glycemic pattern.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Giorgino F, Franco DR, Nicolay C, et al. Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials. Diabetes Care. 2024. PMID: 38530948. doi:10.2337/dc23-2366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。